Global Market Presence CSL Seqirus operates in over 20 countries with manufacturing facilities in the US, UK, Germany, and Australia, presenting multiple entry points for expanding partnerships and sales of influenza vaccines and related pharmaceuticals in key international markets.

Innovative Vaccines The company's focus on developing cell-based and adjuvanted seasonal influenza vaccines along with its active research into vaccines against highly pathogenic avian influenza creates opportunities to supply cutting-edge vaccine solutions to governments and healthcare providers.

Strategic Public Health Collaborations Partnerships with agencies like the US Department of Health and Human Services and ongoing development of mRNA-based vaccines position CSL Seqirus as a strategic vendor for government stockpiles and pandemic preparedness programs.

Community & Specialty Products In Australia and New Zealand, CSL Seqirus markets essential vaccines such as antivenoms and Q fever vaccine, opening avenues to offer these specialty pharmaceutical products to regional health authorities and private healthcare providers.

Research & Data Leadership Recent launches of supporting clinical data and ongoing vaccine development initiatives position CSL Seqirus as a trusted innovator, enabling sales teams to leverage credibility when engaging public health sectors and vaccine resellers seeking proven and advanced influenza solutions.